<DOC>
	<DOCNO>NCT02246075</DOCNO>
	<brief_summary>The purpose study evaluate safety 2 fixed dos EVP-6124 hydrochloride ( HCl ) compare placebo 24 week subject mild moderate Alzheimer 's disease concurrently receive stable treatment memantine currently receive stable treatment previously treat acetylcholinesterase inhibitor .</brief_summary>
	<brief_title>Study Safety Two Doses Investigational Study Drug EVP-6124 Subjects With Alzheimer 's Disease Currently Receiving Memantine</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Ages ≥55 ≤85 year Informed consent form ( ICF ) sign subject legally acceptable representative studyspecific procedure subject perform ICF sign support person/caregiver studyspecific procedure support person/caregiver perform Clinical diagnosis dementia due possible probable AD consistent criterion establish workgroup National Institute Aging Alzheimer 's Disease Association Magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan perform within 12 month screen , finding consistent diagnosis dementia due AD without clinically significant comorbid pathology . If MRI CT scan unavailable occur great 12 month screen , assessment complete finding confirm subject enters runin period ( Day 14 ) ( copy report available study site ) MiniMental State Examination ( MMSE ) score ≥12 ≤26 screening Modified Hachinski Ischemic Scale ( mHIS ) score ≤4 screen Fertile , sexually active subject ( men woman ) must use effective method contraception study . Female subject female partner male subject must surgically sterile ( hysterectomy bilateral tubal ligation ) , postmenopausal least 1year , willing practice adequate method contraception childbearing potential ( defined consistent use combine effective method contraception [ include least 1 barrier method ] ) Reliable capable support person/caregiver , live household , interacts subject regularly help facilitate clinic visit study subject Subject living home , senior residential setting , institutional set without need continuous ( ie , 24hour ) nursing care General health status acceptable participation 24week study Fluency ( oral write ) language standardized test administer Receiving stable dose memantine least 3 month ( 90 day ) screen continuous dose least 3 month . Additional comedication AChEI ( donepezil dose form 23 mg daily ( QD ) , rivastigmine galantamine ) allow stable least 3 month ( 90 day ) screen total continuous exposure least 3 month . Exposure experimental drug , experimental biologic experimental medical device within 2 month ( 60 day ) screen Prior participation amyloid vaccination clinical study time past completion passive amyloid vaccination study within 6 month screen Inability swallow tablet In judgment investigator , inability subject complete 24week study Residence skilled nursing facility Inability ≥75 % compliant singleblind study drug Clinically significant ( judgment investigator ) abnormal serum electrolyte ( sodium , potassium , magnesium ) repeat test Clinically significant untreated hypothyroidism ( treat , thyroidstimulating hormone level thyroid supplementation dose must stable least 6 month screen ) Insufficiently control diabetes mellitus ( judgment investigator ) require insulin Renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) Malignant tumor within 3 year screen ( except squamous basal cell carcinoma cervical carcinoma situ localize prostate cancer ) History ischemic colitis ischemic enterocolitis Unstable medical condition clinically significant judgment investigator Female subject pregnant , nursing , plan become pregnant study Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.5 time upper limit normal History myocardial infarction unstable angina within 6 month screen History 1 myocardial infarction within 5 year screen Clinically significant ( judgment investigator ) cardiac arrhythmia ( include atrial fibrillation ) , cardiomyopathy , cardiac conduction defect ( subject pacemaker acceptable ) Symptomatic hypotension , uncontrolled hypertension ( judgment investigator ) Clinically significant abnormality screen electrocardiogram ( ECG ) , include necessarily limit confirm QTc value ≥450 msec male ≥470 msec female . In subject QRS value &gt; 120msec , QTc value &lt; 500 msec may eligible follow discussion Medical Monitor . Stroke within 18 month screen , history stroke concomitant onset dementia History brain tumor , subdural hematoma , clinically significant ( judgment investigator ) spaceoccupying lesion CT MRI Head trauma clinically significant ( judgment investigator ) loss consciousness within 12 month screen concurrent onset dementia Onset dementia secondary ( judgment investigator ) cardiac arrest , surgery general anesthesia , resuscitation Specific degenerative CNS disease diagnosis AD ( eg , Huntington 's disease , CreutzfeldJacob disease , Down 's syndrome , FrontoTemporal Dementia , Parkinson 's disease ) Wernicke 's encephalopathy Active acute chronic CNS infection Donepezil 23 mg QD currently within 3 month prior randomization Discontinued AChEI &lt; 30 day prior randomization Antipsychotics ; low dos ( judgment investigator , except clozapine ) allow give sleep disturbance , agitation and/or aggression , subject receive stable dose least 3 month randomization Tricyclic antidepressants monoamine oxidase inhibitor ; antidepressant allow subject receive stable dose least 3 month randomization Anxiolytics sedativehypnotics , include barbiturate ( unless give low dos benign tremor ) ; low dos benzodiazepine zolpidem ( judgment investigator ) allow give insomnia/sleep disturbance , subject receive stable dose least 3 month randomization Peripherally act drug effect cholinergic transmission Immunosuppressants , include systemic corticosteroid , take clinically immunosuppressive dos judgment investigator ( Note : steroid use allergy inflammation permit ) Antiepileptic medication take control seizures Chronic intake opioidcontaining analgesic Sedating H1 antihistamine Nicotine therapy ( dosage form include patch ) , varenicline ( Chantix ) , similar therapeutic agent within 30 day screen Clinically significant urine drug screen ( UDS ) serum alcohol test result judgment investigator ( include medical marijuana )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>Alpha-7 nAChR</keyword>
</DOC>